Mazdutide

Sinonimi: LY3305677, IBI362, OXM-3 analog, Glucagon/GLP-1 receptor dual agonist

In the rapidly evolving landscape of metabolic disease therapeutics, dual receptor agonists have captured the spotlight for their ability to deliver robust weight loss and glycemic control beyond what single-target agents can achieve. Mazdutide, a synthetic peptide engineered as a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), has emerged as a promising candidate in this space, drawing interest from pharmaceutical developers and researchers alike. Its unique mechanism taps into both incretin and energy expenditure pathways, offering a differentiated profile that is particularly attractive for next-generation obesity and type 2 diabetes treatments.

Mazdutide is a 29-amino acid peptide analog of oxyntomodulin, a naturally occurring hormone that activates both GCGR and GLP-1R. By incorporating strategic modifications—such as a C-terminal extension and fatty acid side chain—the molecule achieves enhanced stability and prolonged half-life, making it suitable for once-weekly subcutaneous administration. This design allows Mazdutide to simultaneously enhance insulin secretion, suppress appetite, and increase energy expenditure, addressing multiple facets of metabolic dysregulation.

As a research-grade or API-grade peptide, Mazdutide is typically supplied as a lyophilized powder with high purity, often exceeding 98% as determined by HPLC. Its dual agonist activity positions it as a valuable tool for studying receptor co-activation, peptide engineering, and metabolic pathway crosstalk. For companies engaged in the development of multi-receptor agonists or combination therapies, Mazdutide serves as both a benchmark and a building block for further innovation.

Product Overview & Composition

Mazdutide is a synthetic peptide with a molecular formula of C₁₉₂H₂₈₉N₄₇O₅₉ and a molecular weight of approximately 4216.6 Da. It is produced via solid-phase peptide synthesis and subsequent purification steps to achieve high purity. The peptide backbone is modified with a fatty acid moiety to facilitate albumin binding, which extends its circulation time. This structural engineering is critical for its dual agonist functionality and pharmacokinetic profile.

The compound is characterized by its ability to bind to both GCGR and GLP-1R with high affinity, leading to balanced activation of both receptors. This dual action not only improves glycemic control but also promotes satiety and increases energy expenditure, making it a compelling candidate for the treatment of obesity and metabolic disorders.

Key Applications

• Obesity and weight management research: Mazdutide is studied for its effects on reducing body weight through combined appetite suppression and increased energy expenditure.
• Type 2 diabetes therapeutics: Its GLP-1R agonism enhances glucose-dependent insulin secretion, while GCGR activation may improve hepatic lipid metabolism.
• Metabolic syndrome studies: The dual agonist mechanism is explored for addressing multiple components of metabolic syndrome, including dyslipidemia and insulin resistance.
• Receptor co-activation research: Mazdutide serves as a tool compound to investigate the synergistic effects of GCGR and GLP-1R activation.
• Combination therapy development: It is evaluated in combination with other anti-obesity or antidiabetic agents for potential additive or synergistic benefits.

Quality & Standards

Packaging & Supply

• Confezionamento: Supplied in glass vials with rubber stoppers and aluminum crimp seals, available in 1 mg, 5 mg, 10 mg, 50 mg, and 100 mg sizes.
• MOQ: 10 mg (flexible for research quantities).
• Tempi di consegna: 3-5 business days (stock items)
• Documentazione: COA, MSDS, and TDS provided upon request.
• Customization: Custom packaging and labeling available for bulk orders.

Richiesta di preventivo

• LyvBio S.r.l. — E-mail: info@lyvbio.com